• metastatic/advanced - colorectal cancer (mCRC)
• mCRC - (neo)adjuvant (NA)
• mCRC - 1st line (L1) 2
• mCRC - 2nd line (L2) 3
• endometrial cancer 10

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC
• avelumab based treatment
• avelumab plus SoC
• dostarlimab based treatment
• dostarlimab plus soC
• durvalumab based treatment
• durvalumab plus olaparib plus SoC
• durvalumab plus SoC
• pembrolizumab based treatment
• pembrolizumab plus lenvatinib
• pembrolizumab plus SoC
• poly ADP-ribose polymerase (PARP) inhibitor
• niraparib
• VEGF(R) inhibitor
• lenvatinib
• lenvatinib in association

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs placebo plus SoC

  All patients dMMR PDL1 (CPS < 1) PDL1 (CPS >1) pMMR

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

endometrial cancer, pembrolizumab plus SoC vs. chemotherapy, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;